United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 210.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,085 shares of the biotechnology company's stock after acquiring an additional 6,841 shares during the quarter. SG Americas Securities LLC's holdings in United Therapeutics were worth $3,109,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Dunhill Financial LLC increased its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares in the last quarter. State of Wyoming acquired a new position in shares of United Therapeutics in the 4th quarter valued at $62,000. Millstone Evans Group LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at $67,000. Curat Global LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $63,000. Finally, Natixis acquired a new position in shares of United Therapeutics in the 4th quarter valued at $85,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on UTHR. Morgan Stanley upped their price target on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price for the company. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Bank of America decreased their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $393.08.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the transaction, the chief financial officer now directly owns 8,118 shares in the company, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,500 shares of company stock valued at $20,828,390 over the last three months. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

UTHR traded down $2.79 during trading on Friday, reaching $283.35. 564,424 shares of the stock were exchanged, compared to its average volume of 452,793. The business's 50 day moving average price is $300.50 and its two-hundred day moving average price is $330.53. The company has a market capitalization of $12.78 billion, a price-to-earnings ratio of 12.44, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $266.98 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same period in the previous year, the business earned $6.17 earnings per share. United Therapeutics's quarterly revenue was up 17.2% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.